Mylan launches generic Flomax
PITTSBURGH The Food and Drug Administration has approved a generic treatment for a prostate disease made by Mylan, the generic drug maker said Wednesday.
The FDA approved Mylan’s tamsulosin hydrochloride capsules in the 0.4 mg strength, and Mylan has launched the drug. The drug is a generic version of Boehringer Ingelheim’s benign prostatic hyperplasia drug Flomax. Teva and Actavis said Tuesday that they had also launched generic versions of the drug.
Tamsulosin hydrochloride capsules had sales of around $2.2 billion in 2009, according to IMS Health.
NACDS Foundation elects new board members
ALEXANDRIA, Va. The charitable arm of the National Association of Chain Drug Stores has appointed seven new members to its board of directors.
New members of the NACDS Foundation each will serve one-year term, the organization said. Newly elected NACDS Foundation board members include:
- Joseph W. Cavaliere, SVP customer development of Unilever;
- Debbie B. Garza, divisional VP government and community relations at Walgreens;
- William Graham, VP sales at Beiersdorf;
- David Klaum, general manager of Fougera and Nycomed US SVP;
- Louis J. Martire, VP trade development of Energizer Holdings;
- David A. Moules, VP channel development, patient assistance and reimbursement programs of GlaxoSmithKline; and,
- Robert Potter, SVP sales and marketing of Mylan Pharmaceuticals.
“The NACDS Foundation is dedicated to improving and advancing public health and wellness,” said NACDS Foundation president Edith A. Rosato. “Our board, which is truly representative of the pharmacy community –– from retailers and pharmaceutical companies to consumer product businesses –– shares in our commitment to education, research and charity. I applaud the pharmacy community’s support of the Foundation, welcome our new Board members, and look forward to working with them to implement the foundation’s vision and mission.”
Judge upholds patent for Protonix DR
JERUSALEM The U.S. District Court for the District of New Jersey has ruled that a patent covering a drug for gastroesophageal reflux disease is valid, Teva said.
A jury found that U.S. Patent No. 4,758,579, covering the drug Protonix DR (pantoprazole sodium) was valid, though a decision by the District Court judge independent of the jury’s verdict could still invalidate it.
Wyeth marketed the drug before its acquisition by Pfizer last year. Teva began shipping its generic version in December 2007.